- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04986670
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
NutriCare Intervention on Optimizing Nutritional Status, Reducing Treatment-Related Toxicities, and Improving Quality of Life Among Vulnerable Patients With Lung Cancer
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fang Fang Zhang, MD,PhD
- Phone Number: 6176363706
- Email: Fang_Fang.zhang@tufts.edu
Study Contact Backup
- Name: Mary Cohen, MS,RD
- Email: mary_kathryn.cohen@tufts.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The James Cancer Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (18+ years of age)
Newly diagnosed patients with lung cancer (non-small cell and small cell lung cancer):
Patients with stages I-III lung cancer:
1) starting multimodality therapy including chemoradiation (either concurrent or sequential), systemic treatment, or radiation alone; and may be followed by surgery; or 2) starting adjuvant therapy after lung resection ((chemotherapy alone, radiation alone, or chemoradiation (either concurrent or sequential))
- Patients with stage IV lung cancer or recurrent/metastatic:
Eligible at diagnosis and for up to 3 months after starting treatment
o Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-3
Vulnerable patients who meet at least one of the following criteria:
- Economically disadvantaged (household gross monthly income at or below 130% of the Federal Poverty Level)
- Racial and ethnic minorities (African Americans, American Indians and Alaska Natives, Asians and Pacific Islanders, and Hispanics)
- No health insurance
- Elderly patients (ages 65 years or older)
- Reside in rural areas (non-metropolitan counties with less than 50,000 people)
- Voluntarily provide consent, HIPPA authorization form, and consent from treating oncologist.
- Able to speak and read English themselves or with minimal help.
- Able to receive medically-tailored meals for the course of the study if being assigned to the intervention arm, and willing to sign the MTM agreement.
Exclusion Criteria:
- Cognitively unable to consent or have physical or mental limitations that would prevent full participation in the program.
- Have medical conditions that significantly impact digestion, metabolism, or food intake (e.g., surgical loss of esophagus, stomach, or colon; pancreas dysfunction; brain surgery that alters cognition; severe food allergies; etc.) or have active metabolic or digestive illnesses (i.e., Celiac disease, IBS, renal insufficiency, hepatic insufficiency).
- Pregnant or planning to become pregnant during the study.
- Unable to receive medically-tailored meals for the course of the study if being assigned to the intervention arm, including lack of a permanent address to which meals can be delivered (a friend or home address is acceptable given it is used on a consistent basis), not having a fully functioning kitchen with a microwave or oven for cooking, not having a standard-sized refrigerator with a freezer with storage capacity to hold one week's worth of meals; or unwilling to sign the MTM agreement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NutriCare
The oncology care team will provide participants with nutrition toolkit involving printed educational materials, a nutrition prescription, referral to registered dietitians (RDs) for remotely-delivered medical nutrition therapy counseling, and home-delivery of medically tailored meals.
|
Oncology providers will advise participants with lung cancer to follow evidence-based nutrition recommendations using a Nutrition Prescription.
The Nutrition Prescription aims to enhance providers' role in communicating basic nutrition advice to participants with lung cancer.
It contains seven recommendations, adapted from the newly released Cancer Prevention Recommendations by WCRF/AICR with strong evidence-base.
Oncology care providers will assess the nutritional status of patients with lung cancer using PG-SGA Short Form (the Scored Patient-Generated Subjective Global Assessment).
PG-SGA is an interdisciplinary patient assessment in oncology and other chronic catabolic conditions.
The short form contains four patient generated historical components (weight history, food intake symptoms, and activities and function).
Patients will receive a printed copy of a Nutrition Toolkit from providers.
Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit.
The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors.
The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical.
Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
Medical oncology providers will refer participants to oncology RDs for remotely delivered medical nutrition therapy counseling.
For cohort 1, participants will receive nutrition counseling for 8 months.
The counseling will be provided on a weekly basis during the first 6 months and every other week during the last 2 months (for cohort 1 only).
For cohort 2, participants will receive nutrition counseling for 6 months.
The ultimate frequency of nutrition counseling being provided to each participant will also be adjusted according to the participant's preference and needs.
Medically tailored meals will be provided to participants in the intervention group for a total of 24 weeks for both cohorts.
During the first 8 weeks of the intervention, 3 meals/day will be provided each week for a total of 168 meals per participant.
It will be followed by less frequent meal provision during the subsequent 16 weeks following this schedule: 3 meals/day will be provided every other week for the next 8 weeks (a total of 84 meals per participant); and 3 meals/day will be provided every four weeks during the last 8 weeks (a total of 42 meals per participant).
The number of meals provided to each participant may be adjusted according to participant's preference and needs.
|
Active Comparator: NutriTool
The oncology care team will provide participants with a nutrition toolkit involving printed educational materials.
|
Patients will receive a printed copy of a Nutrition Toolkit from providers.
Evidence-based nutrition recommendations have been compiled for cancer survivors from 4 sources into a Nutrition Toolkit.
The sources include: (1) AmericanCancer Society (ACS) Nutrition and Physical Activity Guidelines for Cancer Survivors; (2)World Cancer Research Fund / American Institute for Cancer Research (WFRF/AICR) Cancer Nutrition Guide; (3) National Cancer Institute (NCI) Eating Hints; and (4) National Comprehensive Cancer Network (NCCN) Guidelines for Cancer Survivors.
The Nutrition Toolkit outlines topics about the impact of cancer treatment on dietary intake patterns and quality, strategies to manage treatment-related eating issues, maintaining a healthy weight post treatment, and evidence-based recommendations and practical.
Nutrition Toolkit strategies for improving diet quality and maintaining an optimal weight for cancer survivors.
Monthly emails will be sent to participants to encourage the use of the toolkit with healthy recipes and general nutrition information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nutritional Intake
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in diet quality and intake of key food groups and nutrients as assessed by the National Cancer Institute Diet History Questionnaire (DHQ III)
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Weight
Time Frame: Recorded at each clinical visit. From date of beginning baseline until the date of completing the final (6 or 8 month) study visit, an average of 3-4 clinic visits dependent on course of treatment.
|
Change in weight and percent weight loss as measured in the clinic
|
Recorded at each clinical visit. From date of beginning baseline until the date of completing the final (6 or 8 month) study visit, an average of 3-4 clinic visits dependent on course of treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Compliance
Time Frame: Recorded at each clinical visit. From date of beginning baseline until the date of completing the final (6 or 8 month) study visit, an average of 3-4 clinic visits dependent on course of treatment.
|
Treatment completion (dose reductions and treatment delays) assessed by the treating medical oncologist
|
Recorded at each clinical visit. From date of beginning baseline until the date of completing the final (6 or 8 month) study visit, an average of 3-4 clinic visits dependent on course of treatment.
|
Treatment-related Toxicities
Time Frame: From baseline until the date of completing the 6 months [for cohort 2] or 8 months [for cohort 1] study visit.
|
Rate of treatment-related toxicities assessed by the treating medical oncologist using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE)
|
From baseline until the date of completing the 6 months [for cohort 2] or 8 months [for cohort 1] study visit.
|
Hospitalizations
Time Frame: From baseline until the date of completing the 6 months [for cohort 2] or 8 months [for cohort 1] study visit.
|
Rate of hospitalizations will assessed by medical record review and linkage with discharge data
|
From baseline until the date of completing the 6 months [for cohort 2] or 8 months [for cohort 1] study visit.
|
ED visits
Time Frame: From baseline until the date of completing the 6 months [for cohort 2] or 8 months [for cohort 1] study visit.
|
Rate of ED visits assessed by medical record review and linkage with discharge data
|
From baseline until the date of completing the 6 months [for cohort 2] or 8 months [for cohort 1] study visit.
|
Patient-reported Symptoms
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in patient-reported symptoms (fatigue, pain, nausea, vomiting, appetite loss, and sleep disturbance) as assessed by a Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Patient quality of life
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in quality of life as assessed by EORTC-QLQ-30
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Patient quality of life
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in quality of life as assessed by EORTC-QLQ-LC13
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Patient-reported Functional Outcomes
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in patient-reported functional outcomes (physical, social, and cognitive functioning) assessed by GAD-7
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Patient-reported Functional Outcomes
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in patient-reported functional outcomes (physical, social, and cognitive functioning) assessed by PHQ-9
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Food Insecurity
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in food insecurity measured by the U.S. Department of Agriculture (USDA) Household Food Security Survey
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Gut Microbial Composition
Time Frame: Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Change in gut microbiome via metagenomic whole shotgun sequencing (mWGS)
|
Baseline, 3-month, and 6 months [for cohort 2] or 8 months [for cohort 1]
|
Cancer Mortality
Time Frame: 5-8 Years
|
National Death Index search performed approximately 5 years after the final patient is enrolled.
|
5-8 Years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Program Implementation
Time Frame: From consent through study completion, 6 months [for cohort 2] or 8 months [for cohort 1]
|
(a) participation; (b) retention; (c) compliance
|
From consent through study completion, 6 months [for cohort 2] or 8 months [for cohort 1]
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: FangFang Zhang, MD, PhD, Tufts University
- Principal Investigator: Colleen Spees, PhD, MEd, RD, LD, FAND, Ohio State University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000203
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer Metastatic
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Williams Cancer FoundationSyncromune, Inc.RecruitingCancer | Solid Tumor | Metastatic Cancer | Metastatic Lung Cancer | Metastatic Breast CancerMexico
-
Asana BioSciencesCompletedCancer | Neoplasm Metastasis | Pancreatic Cancer | Metastatic Cancer | Metastatic Lung Cancer | Pancreas Adenocarcinoma | Metastatic Melanoma | Colon Cancer | Colonic Neoplasms | Pancreas Cancer | Non Small Cell Lung Cancer Metastatic | Neoplasm | Pancreas Neoplasm | Metastatic Pancreatic Cancer | Metastatic Colon Cancer and other conditionsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliInstitut Català d'Oncologia; Hospital Universitario Ramon y Cajal; Hospital Arnau... and other collaboratorsRecruitingMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastasis | Metastatic Prostate CancerSpain
-
Genentech, Inc.CompletedNon-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, MelanomaUnited States
-
Yale UniversityNational Cancer Institute (NCI)TerminatedCancer Head Neck | Metastatic Cancer | Metastatic Lung CancerUnited States
Clinical Trials on Nutrition Prescription
-
Tufts UniversityHealth Care District of Palm Beach County; South Florida Hunger Coalition; Jupiter... and other collaboratorsCompleted
-
Oregon Health and Science UniversityLaura and John Arnold FoundationCompleted
-
Ottawa Heart Institute Research CorporationRecruitingCoronary Artery DiseaseCanada
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Unknown
-
Daren K. HeylandSt. Joseph's Healthcare HamiltonCompleted
-
Peking University People's HospitalNot yet recruiting
-
Jing MaNot yet recruitingCoronary Heart DiseaseChina
-
University at BuffaloNational Center for Advancing Translational Sciences (NCATS)CompletedBrain Injury | ConcussionUnited States
-
Radboud University Medical CenterUMC Utrecht; Amsterdam UMC, location VUmc; Maastro Clinic, The Netherlands; Rad...CompletedHead and Neck Neoplasms | Carcinoma, Squamous CellNetherlands
-
Universidade Federal do Rio de JaneiroUnknown